Navigation Links
Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
Date:1/6/2011

generally. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
2. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
4. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
5. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
6. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
7. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
8. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
9. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
10. Lexicon to Present at BIO International Convention
11. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
(Date:10/22/2014)... JERUSALEM , October 22, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused ... today reported positive top-line clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... United States under a U.S. Food ...
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Cytogen,Corporation (NASDAQ: CYTO) today announced that five ... major medical meetings. The,data will include various ... lexidronam injection) in combination settings for,the treatment ... and multiple myeloma, as well as data ...
... from Serial Outpatient Infusion Study in Patients with,Chronic ... Cardiology 56th Annual Scientific Session --, MOUNTAIN VIEW, ... Scios Inc. announced today that an exploratory,920-patient, Phase ... on the primary endpoint, a composite of death ...
Cached Medicine Technology:New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 2New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 3New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 4New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7
(Date:10/25/2014)... global HCIT outsourcing market is forecast to grow at ... 2018 from $35 billion in 2013. The health insurance ... the HCIT outsourcing market. These industries follow the HCIT ... reduce operational and maintenance costs, increase access to IT ... costs), share risk, and quickly implement new technologies. , ...
(Date:10/25/2014)... Madison, WI (PRWEB) October 25, 2014 ... of tax-advantaged medical and other benefits account management ... designed to help employers save on taxes, reduce ... new Suites provide tax savings and the efficient ... can pick the Suite that best meets their ...
(Date:10/25/2014)... WA (PRWEB) October 25, 2014 Homeowners ... insulation has ‘gone bad’ need wonder no more. Clean ... that homeowners should watch out for when it comes ... insulation, according to the article released by Clean Crawls, ... for homeowners that any insulation that has deteriorated, become ...
(Date:10/25/2014)... News) -- Interrupting blood supply to an arm or a ... with the surgery, according to a new study. ... to the heart to be able to operate on it. ... its ability to produce energy because it doesn,t get oxygen. ... muscle, such as an arm or a leg, the body ...
(Date:10/25/2014)... large influx of international aid is needed, and soon, ... of deaths from the widening Ebola crisis, a team ... specially designed mathematical model, the researchers looked at the ... populated county of hard-hit Liberia -- Montserrado County, home ... said that if international aid isn,t delivered to Liberia ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
... that it takes 50,000 lying side by side to equal ... to be highly accurate vehicles for administering medicines and other ... what happens to the tubes after they discharge their medical ... Now, Stanford researchers, who spent months tracking the tiny tubes ...
... the climate but unless we harness the powers of our ... losing battle, according to an article in the February 2008 ... atmosphere. Arrogant organisms that we are, it is easy to ... Dr Dave Reay from the University of Edinburgh. In truth ...
... board member, health risk, appraisal (HRA) pioneer, and successful ... QualityMetric today announced,the return of James E. Dewey, ... whose new title is Chief Innovation and Research Officer ... Executive,Officer and co- founder., "As CIRO, Jim will ...
... will,present at the Merrill Lynch Global Pharmaceutical, Biotechnology ... Thomas C. Freyman,executive vice president, finance and chief ... company at 9:20 a.m. Central time., A ... accessible through,Abbott,s Investor Relations Web site at ...
... Cash Proceeds from Private Placement of,Restricted Stock and ... Equity, CEDAR KNOLLS, N.J., Jan. 29 ... specializing in,portable electronic medical records management solutions, today ... $1.95 million from three,separate private placement transactions., ...
... 29 Quest Diagnostics,Incorporated (NYSE: DGX ), ... services, announced that it is scheduled to speak,at ... January,30, 2008, at the Langham Hotel, Boston, Massachusetts. ... 8:00 a.m. Eastern Time., During the conference, ...
Cached Medicine News:Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3Health News:QualityMetric Appoints Chief Innovation and Research Officer 2Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 2Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 3Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 4Health News:Quest Diagnostics to Speak at Wachovia Securities 2008 Healthcare Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: